Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Chinese Patent Office
UBS
Julphar
Covington
US Department of Justice
Deloitte
Queensland Health
Cantor Fitzgerald

Generated: September 21, 2018

DrugPatentWatch Database Preview

Forest Labs Company Profile

« Back to Dashboard

What is the competitive landscape for FOREST LABS, and when can generic versions of FOREST LABS drugs launch?

FOREST LABS has twenty-one approved drugs.

There are seventeen US patents protecting FOREST LABS drugs.

Summary for Forest Labs
US Patents:17
Tradenames:18
Ingredients:13
NDAs:21

Drugs and US Patents for Forest Labs

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Forest Labs Llc SAPHRIS asenapine maleate TABLET;SUBLINGUAL 022117-003 Mar 12, 2015 RX Yes No ➤ Sign Up ➤ Sign Up
Forest Labs Llc NAMENDA XR memantine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 022525-001 Jun 21, 2010 AB RX Yes No 8,329,752*PED ➤ Sign Up Y ➤ Sign Up
Forest Labs Llc NAMENDA XR memantine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 022525-004 Jun 21, 2010 AB RX Yes Yes 8,329,752*PED ➤ Sign Up Y ➤ Sign Up
Forest Labs Llc NAMENDA XR memantine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 022525-001 Jun 21, 2010 AB RX Yes No 8,283,379*PED ➤ Sign Up Y ➤ Sign Up
Forest Labs DURAPHYL theophylline TABLET, EXTENDED RELEASE;ORAL 088505-001 Apr 3, 1985 DISCN No No ➤ Sign Up ➤ Sign Up
Forest Labs Inc ZENPEP pancrelipase (amylase;lipase;protease) CAPSULE, DELAYED RELEASE;ORAL 022210-002 Aug 27, 2009 RX Yes No 8,246,950 ➤ Sign Up ➤ Sign Up
Forest Labs Inc VIOKACE pancrelipase (amylase;lipase;protease) TABLET;ORAL 022542-001 Mar 1, 2012 RX Yes No ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Forest Labs

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Forest Labs Llc NAMENDA XR memantine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 022525-003 Jun 21, 2010 5,061,703*PED ➤ Sign Up
Forest Labs COMBUNOX ibuprofen; oxycodone hydrochloride TABLET;ORAL 021378-001 Nov 26, 2004 4,569,937 ➤ Sign Up
Forest Labs Llc NAMENDA XR memantine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 022525-004 Jun 21, 2010 5,061,703*PED ➤ Sign Up
Forest Labs Llc NAMENDA XR memantine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 022525-002 Jun 21, 2010 5,061,703*PED ➤ Sign Up
Forest Labs Llc NAMENDA XR memantine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 022525-001 Jun 21, 2010 5,061,703*PED ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for FOREST LABS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Sublingual Tablets 2.5 mg ➤ Subscribe 2017-07-27
➤ Subscribe Extended-release Capsules 7 mg, 14 mg, 21 mg, and 28 mg ➤ Subscribe 2013-08-16
➤ Subscribe Extended-release Capsules 7 mg, 14 mg, 21 mg ➤ Subscribe 2013-06-17
➤ Subscribe Sublingual Tablets 5 mg and 10 mg ➤ Subscribe 2013-08-13
➤ Subscribe Extended-release Capsules 28 mg ➤ Subscribe 2013-06-12
➤ Subscribe Extended-release Capsules 7 mg, 14 mg, 21 mg, and 28 mg ➤ Subscribe 2013-06-10

Non-Orange Book US Patents for Forest Labs

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,293,229 Methods of producing stable pancreatic enzyme compositions ➤ Sign Up
8,058,291 Methods and compositions for the treatment of CNS-related conditions ➤ Sign Up
7,619,007 Method and composition for administering an NMDA receptor antagonist to a subject ➤ Sign Up
2,012,058,182 ➤ Sign Up
8,580,858 Compositions for the treatment of CNS-related conditions ➤ Sign Up
8,338,486 Methods for the treatment of CNS-related conditions ➤ Sign Up
8,426,472 Method and composition for administering an NMDA receptor antagonist to a subject ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for Forest Labs Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB02/049 United Kingdom ➤ Sign Up PRODUCT NAME: ESCITALOPRAM OXALATE; REGISTERED: SE 17084/85/86/87 20011207; UK PL 13761/0008 20020610; UK PC 13761/0009 20020610; UK PL 13761/0010 20020610; UK PL 13761/0011 20020610; UK PL 13761/0012 20020610; UK PL 13761/0013 20020610; UK PL 13761/00014 20020610; UK PL 13761/0015 20020610
C/GB10/012 United Kingdom ➤ Sign Up PRODUCT NAME: A COMBINATION OF ACYCLOVIR AND HYDROCORTISONE; REGISTERED: UK PL18191/0001-0001 20091112
0746317/01 Switzerland ➤ Sign Up PRODUCT NAME: ASENAPINUM; REGISTRATION NO/DATE: SWISSMEDIC 62073 20.07.2012
C0056 France ➤ Sign Up PRODUCT NAME: ASENAPINE; REGISTRATION NO/DATE: EU/1/10/640/001 20100901
2010000050 Germany ➤ Sign Up PRODUCT NAME: ASENAPINHALTIGES ARZNEIMITTEL; REGISTRATION NO/DATE: EU/1/10/640/001-006 20100901
90035-5.L Sweden ➤ Sign Up PRODUCT NAME: ASENAPIN; REG. NO/DATE: EU/1/10/640/001 20100901
02C/039 Belgium ➤ Sign Up PRODUCT NAME: ESCITALOPRAM. OXALAT. (INN) ESCITALOPRAM; NATL. REGISTRATION NO/DATE: 7004 IE10 F 3 20020729; FIRST REGISTRATION: SE 17084 20011207
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Baxter
Cipla
Chubb
Julphar
Argus Health
Harvard Business School
UBS
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.